8-K: Skye Bioscience Secures $50.25 Million in Private Placement to Advance Clinical Programs

Skye Bioscience has successfully raised $50.25 million through a private placement to fund its clinical trials for obesity and glaucoma treatments.

Summary

• Skye Bioscience has entered into a securities purchase agreement for a private placement, raising $50.25 million before fees and expenses.
• The financing includes the sale of 11,822,124 shares of common stock at $2.305 per share and pre-funded warrants to purchase up to 9,978,739 shares at $2.3049 per warrant.
• The pre-funded warrants are immediately exercisable at $0.001 per share and do not expire until fully exercised.
• The private placement is expected to close on or about January 31, 2024, subject to customary closing conditions.
• The funds are intended to support operations into early 2026, including a Phase 2 clinical trial for nimacimab in obesity, Phase 2a and 2b trials for SBI-100 Ophthalmic Emulsion in glaucoma and ocular hypertension, and ongoing R&D.
• The Phase 2 obesity trial will randomize approximately 200 obese patients into four arms: nimacimab, a GLP-1R agonist, a combination of both, or a placebo.
• The primary endpoint for the obesity trial is the percent change in weight from baseline at week 26, with secondary endpoints including safety, tolerability, and changes in waist circumference, body composition, and blood markers.
• Interim data for the Phase 2 obesity trial is expected in Q1 2025, with preliminary topline data expected in 2025.
• Interim data for the Phase 2a glaucoma trial is expected in Q1 2024, with preliminary topline data in Q2 2024.
• The Phase 2b glaucoma trial is anticipated to start in H2 2024, with preliminary topline data expected in 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise, which will fund the company's operations and clinical trials into early 2026. The company's focus on innovative treatments for obesity and glaucoma, along with the participation of specialist life science investors, further contributes to the positive outlook.

Positives

• The $50.25 million private placement provides substantial funding for Skye Bioscience's clinical programs.
• The financing is expected to support operations into early 2026, providing a significant runway for development.
• The planned Phase 2 trial for nimacimab in obesity is designed to evaluate the drug both as a monotherapy and in combination with a GLP-1R agonist.
• The company has multiple clinical trials underway or planned, targeting both obesity and glaucoma.
• The company has attracted a strong syndicate of specialist life science investors.

Negatives

• The private placement involves the issuance of new shares, which may dilute existing shareholders.
• The clinical trial designs are not finalized and remain subject to change based on further input from advisors and the U.S. FDA.
• The company is still in the clinical stage, and there is no guarantee of successful outcomes for the trials.

Risks

• Clinical trial results may not be positive, which could impact the company's future prospects.
• Regulatory approvals are not guaranteed, and delays could occur.
• The company may require additional funding in the future if the current financing is insufficient.
• Changes in the competitive landscape could impact the commercial potential of the company's products.
• The planned Phase 2 clinical trial design is not finalized and remains subject to change based on further input from advisors and the U.S. FDA.

Future Outlook

The company expects the net proceeds from the private placement to fund operations into early 2026, supporting key milestones in its clinical development programs for obesity and glaucoma.

Management Comments

• Punit Dhillon, CEO and Chair of Skye, stated that the funding allows the company to pursue a high-impact clinical strategy for nimacimab.
• He also noted the potential of peripheral CB1 inhibition in obesity treatment and the opportunity for SBI-100 OE in glaucoma.

Industry Context

The announcement comes as the obesity market is experiencing significant clinical and commercial advancements with new drugs, highlighting the potential for complementary mechanisms like peripheral CB1 inhibition. The glaucoma market also presents an opportunity for new classes of intraocular pressure-lowering drugs.

Comparison to Industry Standards

• The planned Phase 2 trial for nimacimab in obesity, which includes a combination arm with a GLP-1R agonist, is in line with current industry trends exploring combination therapies for enhanced weight loss.
• The company's focus on peripheral CB1 inhibition is a differentiated approach compared to traditional appetite suppressants, potentially offering a unique mechanism for fat loss and metabolic benefits.
• The development of SBI-100 Ophthalmic Emulsion addresses the need for new classes of intraocular pressure-lowering drugs, as the glaucoma market has seen limited innovation in recent years, with Rhopressa being a notable exception in 2017.
• The company's approach of targeting the endocannabinoid system aligns with a growing interest in this pathway for therapeutic development, although it is still considered an emerging area.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability and ability to advance clinical programs.
• Patients with obesity and glaucoma may benefit from the development of new treatment options.
• Investors will have the opportunity to participate in the potential success of the company's clinical programs.

Next Steps

• The company will close the private placement on or about January 31, 2024.
• The company will initiate a Phase 2 clinical trial for nimacimab in obesity in mid-2024.
• The company will continue enrollment in the Phase 2a clinical trial for SBI-100 Ophthalmic Emulsion.
• The company will start a Phase 2b trial of SBI-100 OE in H2 2024.
• The company will file a registration statement with the SEC for the resale of the shares and warrant shares issued in the private placement within 60 days.

Key Dates

Keywords

private placement, clinical trial, nimacimab, obesity, glaucoma, SBI-100 Ophthalmic Emulsion, CB1 inhibitor, GLP-1R agonist, biotechnology, endocannabinoid system